Clinical trials: Metabolic Dysfunction-associated Steatohepatitis, open to volunteers
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with MASLD, particularly in the setting of compensated…
- Trial name
- S-MASH (NCT07440511)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors
The Development of MASLD Among Survivors of Breast or Colorectal Cancer
A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly.
- Conditions
- Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- EVALUATE (NCT07280143)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Bern
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)
The study will evaluate whether betaine reduces liver injury in people with metabolic dysfunction-associated steatohepatitis (MASH). MASH is a type of liver disease that occurs in some people with fatty liver.
- Trial name
- NCT07276204
- Testing
- Betaine
- Volunteers
- 70 people
- Sponsor
- Southern California Institute for Research and Education
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
To determine the effect of MTHF supplementation on serum folate and homocysteine level, metabolic, nutritional status, liver function, and PPARα and TNFα gene expression in patients with MASLD
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- MASLD (NCT07740109)
- Testing
- 5-methyltetrahydrofolate (5-MTHF)
- Where
- Iran
- Volunteers
- 44 people
- Sponsor
- Tabriz University of Medical Sciences
Metabolic Dysfunction-Associated Steatotic Liver Disease
Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease
Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation.
- Trial name
- NCT07373769
- Testing
- Ultrasound and magentic resonance imaging
- Where
- Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
- Trial name
- NCT07632677
- Testing
- iLivTouch (Vibration-controlled transient elastography)
- Where
- 22 sites in China
- Volunteers
- 10,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Non-Alcoholic Fatty Liver Disease
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the…
- Trial name
- NCT05332613
- Testing
- TRE plus SOC, SOC, TRE
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated…
- Trial name
- NCT06920043
- Testing
- Efimosfermin
- Where
- 30 sites in United States
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
NAFLD, Cardiac Disease
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease.
- Conditions
- NAFLD, Cardiac Disease, Fatty Liver, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT06386094
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Resmiterom Efficacy & Safety in Patients With MASH
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
- Trial name
- REZMASH (NCT07249788)
- Testing
- Resmetirom
- Where
- Pakistan
- Volunteers
- 165 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Non-alcoholic Fatty Liver Disease
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and…
- Trial name
- ZENITH-1 (NCT07221227)
- Testing
- Efimosfermin alfa
- Where
- 91 sites in United States, Australia and 7 more
- Volunteers
- 1,200 people
- Sponsor
- GlaxoSmithKline
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
MAFLD
Liver Stiffness Changes by iLivTouch to Predict Liver-Related Events in MAFLD
This is an observational study (multicenter retrospective real-world cohort study). The purpose of this study is to assess the predictive performance of liver stiffness measurement (LSM, including baseline LSM1, current LSMC and…
- Trial name
- MAFLD (NCT07777198)
- Volunteers
- 2,303 people
- Sponsor
- Beijing Friendship Hospital
Menopause, Metabolic Dysfunction Associated Steatotic Liver Disease
COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, currently affecting approximately 1-in-4 people globally.
- Trial name
- NCT06704516
- Testing
- Menopausal hormone therapy
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Oxford